Life Extension Final Clerance Sale

Life Extension Magazine

Life Extension Magazine November 2013
Report  

Enjoy Estrogen’s Multiple Benefits While Guarding Against Potential Risks

By William Faloon

References

  1. Fichera M, Rinaldi N, Tarascio M, et al. Indications and controindications of hormone replacement therapy in menopause. Minerva Ginecol. 2013 Jun;65(3):331-44.
  2. Canderelli R, Leccesse LA, Miller NL, Unruh Davidson J. Benefits of hormone replacement therapy in postmenopausal women. J Am Acad Nurse Pract. 2007 Dec;19(12):635-41.
  3. Tao M, Teng Y, Shao H, Wu P, Mills EJ. Knowledge, perceptions and information about hormone therapy (HT) among menopausal women: a systematic review and meta-synthesis. PLoS One. 2011;6(9):e24661.
  4. Lin JH, Morikawa T, Chan AT, et al. Postmenopausal hormone therapy is associated with a reduced risk of colorectal cancer lacking CDKN1A expression. Cancer Res. 2012 Jun 15;72(12):3020-8.
  5. Gompel A. Micronized progesterone and its impact on the endometrium and breast vs. progestogens. Climacteric. 2012 Apr;15 Suppl 1:18-25.
  6. Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat. 2007 Jan;101(2):125-34.
  7. Ambrosone CB, McCann SE, Freudenheim JL, Marshall JR, Zhang Y, Shields PG. Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. J Nutr. 2004 May;134(5):1134-8.
  8. Deitz AC, Zheng W, Leff MA, et al. N-Acetyltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):905-10.
  9. Abbas S, Linseisen J, Slanger T, et al. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer--results of a large case-control study. Carcinogenesis. 2008 Jan;29(1):93-9.
  10. Dumitrescu RG, Cotarla I. Understanding breast cancer risk -- where do we stand in 2005? J Cell Mol Med. 2005 Jan-Mar;9(1):208-21.
  11. Dietrich W, Gaba A, Zhegu Z, et al. Testosterone dependent androgen receptor stabilization and activation of cell proliferation in primary human myometrial microvascular endothelial cells. Fertil Steril. 2011 Mar 15;95(4):1247-55.e1-2.
  12. Garland CF, Gorham ED, Mohr SB, et al. Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):708-11.
  13. Hollis BW, Marshall DT, Savage SJ, Garrett-Mayer E, Kindy MS, Gattoni-Celli S. Vitamin D3 supplementation, low-risk prostate cancer, and health disparities. J Steroid Biochem Mol Biol. 2013 Jul;136:233-7.
  14. Kennel KA, Drake MT. Vitamin D in the cancer patient. Curr Opin Support Palliat Care. 2013 Sep;7(3):272-7.
  15. Liu X, Lv K. Cruciferous vegetables intake is inversely associated with risk of breast cancer: a meta-analysis. Breast. 2013 Jun;22(3):309-13.
  16. Liu B, Mao Q, Cao M, Xie L. Cruciferous vegetables intake and risk of prostate cancer: a meta-analysis. Int J Urol. 2012 Feb;19(2):134-41.
  17. Kandala PK, Srivastava SK. DIMming ovarian cancer growth. Curr Drug Targets. 2012 Dec;13(14):1869-75.
  18. Messina MJ, Wood CE. Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary. Nutr J. 2008 Jun 3;7:17.
  19. Hedlund TE, Johannes WU, Miller GJ. Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro. Prostate. 2003 Jan 1;54(1):68-78.
  20. Douglas CC, Johnson SA, Arjmandi BH. Soy and its isoflavones: The truth behind the science in breast cancer. Anticancer Agents Med Chem. 2013 Aug 6. [Epub ahead of print]
  21. Available at: http://www.altmedrev.com/publications/7/4/336.pdf. Accessed August 8, 2013.
  22. Walaszek Z, Szemraj J, Narog M, et al. Metabolism, uptake, and excretion of a D-glucaric acid salt and its potential use in cancer prevention. Cancer Detect Prev. 1997;21(2):178-90.
  23. Touillaud MS, Thiébaut AC, Fournier A, Niravong M, Boutron-Ruault MC, Clavel-Chapelon F. Dietary lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status. J Natl Cancer Inst. 2007 Mar 21;99(6):475-86.
  24. Schmid HP, Fischer C, Engeler DS, Bendhack ML, Schmitz-Dräger BJ. Nutritional aspects of primary prostate cancer prevention. Recent Results Cancer Res. 2011;188:101-7.
  25. Taylor EF, Burley VJ, Greenwood DC, Cade JE. Meat consumption and risk of breast cancer in the UK Women’s Cohort Study. Br J Cancer. 2007 Apr 10;96(7):1139-46.
  26. Cui X, Dai Q, Tseng M, Shu XO, Gao YT, Zheng W. Dietary patterns and breast cancer risk in the shanghai breast cancer study. Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1443-8.
  27. Burzynski SR. Aging: gene silencing or gene activation? Med Hypotheses. 2005;64(1):201-8.
  28. Gorbunova V, Seluanov A. Making ends meet in old age: DSB repair and aging. Mech Ageing Dev. 2005 Jun-Jul;126(6-7):621-8.
  29. Simone CB. Cancer and Nutrition. Lawrenceville, NJ: Princeton Institute; 2005.
  30. Ombra MN, Di Santi A, Abbondanza C, Migliaccio A, Avvedimento EV, Perillo B. Retinoic acid impairs estrogen signaling in breast cancer cells by interfering with activation of LSD1 via PKA. Biochim Biophys Acta. 2013 May;1829(5):480-6.
  31. Lobenhofer EK, Huper G, Iglehart JD, Marks JR. Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ. 2000 Feb;11(2):99-110.
  32. Dimitrov V, Salehi-Tabar R, An BS, White JH. Non-classical mechanisms of transcriptional regulation by the vitamin D receptor: Insights into calcium homeostasis, immune system regulation and cancer chemoprevention. J Steroid Biochem Mol Biol. 2013 Jul 30. pii: S0960-0760(13)00141-6.
  33. Chatterjee M. Vitamin D and genomic stability. Mutat Res. 2001 Apr 18;475(1-2):69-87.
  34. Kim YS, Milner JA. Targets for indole-3-carbinol in cancer prevention. J Nutr Biochem. 2005 Feb;16(2):65-73.
  35. Deng XS, Tuo J, Poulsen HE, Loft S. Prevention of oxidative DNA damage in rats by brussels sprouts. Free Radic Res. 1998 Mar;28(3):323-33.
  36. Xie SP, Pirianov G, Colston KW. Vitamin D analogues suppress IGF-I signalling and promote apoptosis in breast cancer cells. Eur J Cancer. 1999 Nov;35(12):1717-23.
  37. Lowe L, Hansen CM, Senaratne S, Colston KW. Mechanisms implicated in the growth regulatory effects of vitamin D compounds in breast cancer cells. Recent Results Cancer Res. 2003;164:99-110.
  38. Crew KD, Gammon MD, Steck SE, et al. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila). 2009 Jun;2(6):598-604.
  39. Lee HJ, Ji Y, Paul S, Maehr H, Uskokovic M, Suh N. Activation of bone morphogenetic protein signaling by a Gemini vitamin D3 analogue is mediated by Ras/protein kinase C alpha. Cancer Res. 2007 Dec 15;67(24):11840-7.
  40. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007 Jun;85(6):1586-91.
  41. Aloia JF, Patel M, Dimaano R, et al. Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. Am J Clin Nutr. 2008 Jun;87(6):1952-8.
  42. Mocanu V, Stitt PA, Costan AR, et al. Long-term effects of giving nursing home residents bread fortified with 125 microg (5000 IU) vitamin D(3) per daily serving. Am J Clin Nutr. 2009 Apr;89(4):1132-7.
  43. Michnovicz JJ, Adlercreutz H, Bradlow HL. Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. J Natl Cancer Inst. 1997 May 21;89(10):718-23.
  44. Dalessandri KM, Firestone GL, Fitch MD, Bradlow HL, Bjeldanes LF. Pilot study: effect of 3,3’-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr Cancer. 2004;50(2):161-7.
  45. Tomczyk J, Olejnik A. Sulforaphane--a possible agent in prevention and therapy of cancer. Postepy Hig Med Dosw (Online). 2010 Nov 29;64:590-603.
  46. Kumar A, Sabbioni G. New biomarkers for monitoring the levels of isothiocyanates in humans. Chem Res Toxicol. 2010 Apr 19;23(4):756-65.
  47. Rose P, Faulkner K, Williamson G, Mithen R. 7-Methylsulfinylheptyl and 8-methylsulfinyloctyl isothiocyanates from watercress are potent inducers of phase II enzymes. Carcinogenesis. 2000 Nov;21(11):1983-8.
  48. Bradlow HL, Davis DL, Lin G, Sepkovic D, Tiwari R. Effects of pesticides on the ratio of 16 alpha/2-hydroxyestrone: a biologic marker of breast cancer risk. Environ Health Perspect. 1995 Oct;103 Suppl 7:147-50.
  49. Available at: http://bwww.breasthealthproject.com/documents/EstrogenMetabolismandRiskofBreastCancer.pdf. Accessed August 9, 2013. Muti P, Bradlow HL, Micheli A, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology. 2000 Nov;11(6):635-40.
  50. Muti P, Bradlow HL, Micheli A, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology. 2000 Nov;11(6):635-40.
  51. Yoo HJ, Sepkovic DW, Bradlow HL, Yu GP, Sirilian HV, Schantz SP. Estrogen metabolism as a risk factor for head and neck cancer. Otolaryngol Head Neck Surg. 2001 Mar;124(3):241-7.
  52. Kabat GC, Chang CJ, Sparano JA, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):505-9.
  53. Kabat GC, O’Leary ES, Gammon MD, et al. Estrogen metabolism and breast cancer. Epidemiology. 2006 Jan;17(1):80-8.
  54. Fowke JH, Longcope C, Hebert JR. Brassica vegetable consumption shifts estrogen metabolism in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2000 Aug;9(8):773-9.
  55. Fowke JH, Qi D, Bradlow HL, et al. Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection. Steroids. 2003 Jan;68(1):65-72.
  56. Cover CM, Hsieh SJ, Cram EJ, ET AL. Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res. 1999 Mar 15;59(6):1244-51.
  57. Sharma S, Stutzman JD, Kelloff GJ, Steele VE. Screening of potential chemopreventive agents using biochemical markers of carcinogenesis. Cancer Res. 1994 Nov 15;54(22):5848-55.
  58. Messina M, Watanabe S, Setchell KD. Report on the 8th International Symposium on the Role of Soy in Health Promotion and Chronic Disease Prevention and Treatment. J Nutr. 2009 Apr;139(4):796S-802S.
  59. Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control. 1998 Dec;9(6):553-7.
  60. Wu AH, Wan P, Hankin J, Tseng CC, Yu MC, Pike MC. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis. 2002 Sep;23(9):1491-6.
  61. Messina MJ. Legumes and soybeans: overview of their nutritional profiles and health effects. Am J Clin Nutr. 1999 Sep;70(3 Suppl):439S-450S.
  62. Yanagihara K, Takigahira M, Mihara K, et al. Inhibitory effects of isoflavones on tumor growth and cachexia in newly established cachectic mouse models carrying human stomach cancers. Nutr Cancer. 2013;65(4):578-89.
  63. Yang G, Shu XO, Chow WH, et al. Soy food intake and risk of lung cancer: evidence from the Shanghai Women’s Health Study and a meta-analysis. Am J Epidemiol. 2012 Nov 15;176(10):846-55.
  64. Santos MA, Silva RF, Medeiros VP, et al. Effects of different doses of soy isoflavones on bone tissue of ovariectomized rats. Climacteric. 2013 Aug 9. [Epub ahead of print]
  65. Matori H, Umar S, Nadadur RD, et al. Genistein, a soy phytoestrogen, reverses severe pulmonary hypertension and prevents right heart failure in rats. Hypertension. 2012 Aug;60(2):425-30.
  66. Yamamoto S, Sobue T, Kobayashi M, et al. Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst. 2003 Jun 18;95(12):906-13.
  67. Barnes S. Effect of genistein on in vitro and in vivo models of cancer. J Nutr. 1995 Mar;125(3 Suppl):777S-783S.
  68. Setchell KD. Soy isoflavones--benefits and risks from nature’s selective estrogen receptor modulators (SERMs). J Am Coll Nutr. 2001 Oct;20(5 Suppl):354S-362S; discussion 381S-383S.
  69. Lee HP, Gourley L, Duffy SW, Estéve J, Lee J, Day NE. Dietary effects on breast-cancer risk in Singapore. Lancet. 1991 May 18;337(8751):1197-200.
  70. Horn-Ross PL, John EM, Canchola AJ, Stewart SL, Lee MM. Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst. 2003 Aug 6;95(15):1158-64.
  71. Ollberding NJ, Lim U, Wilkens LR, et al. Legume, soy, tofu, and isoflavone intake and endometrial cancer risk in postmenopausal women in the multiethnic cohort study. J Natl Cancer Inst. 2012 Jan 4;104(1):67-76.
  72. Palacios S, Pornel B, Vázquez F, Aubert L, Chantre P, Marès P. Long-term endometrial and breast safety of a specific, standardized soy extract. Climacteric. 2010 Aug;13(4):368-75.
  73. Steinberg FM, Murray MJ, Lewis RD, et al. Clinical outcomes of a 2-y soy isoflavone supplementation in menopausal women. Am J Clin Nutr. 2011 Feb;93(2):356-67.
  74. Key TJ, Schatzkin A, Willett WC, Allen NE, Spencer EA, Travis RC. Diet, nutrition and the prevention of cancer. Public Health Nutr. 2004 Feb;7(1A):187-200.
  75. Gonzalez CA. Nutrition and cancer: the current epidemiological evidence. Br J Nutr. 2006 Aug;96 Suppl 1:S42-5.
  76. Tetè S, Nicoletti M, Saggini A, et al. Nutrition and cancer prevention. Int J Immunopathol Pharmacol. 2012 Jul-Sep;25(3):573-81.
  77. Ronco AL, De Stefani E, Deneo-Pellegrini H. Risk factors for premenopausal breast cancer: a case-control study in Uruguay. Asian Pac J Cancer Prev . 2012;13(6):2879-86.
  78. Shannon J, Ray R, Wu C, etal. Food and botanical groupings and risk of breast cancer: a case-control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):81-90.
  79. Ponnampalam EN, Mann NJ, Sinclair AJ. Effect of feeding systems on omega-3 fatty acids, conjugated linoleic acid and trans fatty acids in Australian beef cuts: potential impact on human health. Asia Pac J Clin Nutr. 2006;15(1):21-9.
  80. Kim J, Lim SY, Shin A, et al. Fatty fish and fish omega-3 fatty acid intakes decrease the breast cancer risk: a case-control study. BMC Cancer. 2009 Jun 30;9:216.
  81. Kuriki K, Hirose K, Wakai K, et al. Breast cancer risk and erythrocyte compositions of n-3 highly unsaturated fatty acids in Japanese. Int J Cancer. 2007 Jul 15;121(2):377-85.
  82. Maillard V, Bougnoux P, Ferrari P, et al. N-3 and N-6 fatty acids in breast adipose tissue and relative risk of breast cancer in a case-control study in Tours, France. Int J Cancer. 2002 Mar 1;98(1):78-83.
  83. Available at: http://www.bmj.com/content/346/bmj.f3706. Accessed August 22, 2013.
  84. Available at: http://www.cancer.gov/cancertopics/understandingcancer/environment/AllPages. Accessed August 15, 2013.
  85. Walaszek Z, Hanausek M, Sherman U, Adams AK. Antiproliferative effect of dietary glucarate on the Sprague-Dawley rat mammary gland. Cancer Lett. 1990 Jan;49(1):51-7.
  86. Heerdt AS, Young CW, Borgen PI. Calcium glucarate as a chemopreventive agent in breast cancer. Isr J Med Sci. 1995 Feb-Mar;31(2-3):101-5.
  87. Slaga TJ, Quilici-Timmcke J. D-Glucarate: A Nutrient Against Cancer. Columbus, Ohio: McGraw-Hill; 1999.
  88. Walaszek Z, Hanausek-Walaszek M, Minton JP, Webb TE. Dietary glucarate as anti-promoter of 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis. Carcinogenesis. 1986 Sep;7(9):1463-6.
  89. Abou-Issa H, Moeschberger M, el-Masry W, Tejwani S, Curley RW Jr, Webb TE. Relative efficacy of glucarate on the initiation and promotion phases of rat mammary carcinogenesis. Anticancer Res. 1995 May-Jun;15(3):805-10.
  90. McCann SE, Muti P, Vito D, Edge SB, Trevisan M, Freudenheim JL. Dietary lignan intakes and risk of pre- and postmenopausal breast cancer. Int J Cancer. 2004 Sep 1;111(3):440-3.
  91. Momekov G, Konstantinov S, Dineva I, Ionkova I. Effect of justicidin B - a potent cytotoxic and pro-apoptotic arylnaphtalene lignan on human breast cancer-derived cell lines. Neoplasma. 2011;58(4):320-5.
  92. Lindahl G, Saarinen N, Abrahamsson A, Dabrosin C. Tamoxifen, flaxseed, and the lignan enterolactone increase stroma- and cancer cell-derived IL-1Ra and decrease tumor angiogenesis in estrogen-dependent breast cancer. Cancer Res. 2011 Jan 1;71(1):51-60.
  93. Thompson LU, Chen JM, Li T, Strasser-Weippl K, Goss PE. Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Clin Cancer Res. 2005 May 15;11(10):3828-35.
  94. Boccardo F, Lunardi G, Guglielmini P, et al. Serum enterolactone levels and the risk of breast cancer in women with palpable cysts. Eur J Cancer. 2004 Jan;40(1):84-9.
  95. Rižner TL. Estrogen biosynthesis, phase I and phase II metabolism, and action in endometrial cancer. Mol Cell Endocrinol. 2013 Jul 30. pii: S0303-7207(13)00320-1.
  96. Bailey HH, Mukhtar H. Green tea polyphenols and cancer chemoprevention of genitourinary cancer. Am Soc Clin Oncol Educ Book. 2013;2013:92-6.
  97. Thangapazham RL, Passi N, Maheshwari RK. Green tea polyphenol and epigallocatechin gallate induce apoptosis and inhibit invasion in human breast cancer cells. Cancer Biol Ther. 2007 Dec;6(12):1938-43.
  98. Thangapazham RL, Singh AK, Sharma A, Warren J, Gaddipati JP, Maheshwari RK. Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett. 2007 Jan 8;245(1-2):232-41.
  99. Leong H, Mathur PS, Greene GL. Inhibition of mammary tumorigenesis in the C3(1)/SV40 mouse model by green tea. Breast Cancer Res Treat. 2008 Feb;107(3):359-69.
  100. Masuda M, Suzui M, Lim JT, Deguchi A, Soh JW, Weinstein IB. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J Exp Ther Oncol. 2002 Nov-Dec;2(6):350-9.
  101. Farabegoli F, Barbi C, Lambertini E, Piva R. (-)-Epigallocatechin-3-gallate downregulates estrogen receptor alpha function in MCF-7 breast carcinoma cells. Cancer Detect Prev. 2007;31(6):499-504.
  102. Hsuuw YD, Chan WH. Epigallocatechin gallate dose-dependently induces apoptosis or necrosis in human MCF-7 cells. Ann N Y Acad Sci. 2007 Jan;1095:428-40.
  103. Available at: http://www.fasebj.org/cgi/content/meeting_abstract/22/1_MeetingAbstracts/1164.3. Accessed August 19, 2013.
  104. Wu AH, Yu MC, Tseng CC, Hankin J, Pike MC. Green tea and risk of breast cancer in Asian Americans. Int J Cancer. 2003 Sep 10;106(4):574-9.
  105. Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health. 2006 Feb;96(2):252-61.
  106. Samuel S, Sitrin MD. Vitamin D’s role in cell proliferation and differentiation. Nutr Rev. 2008 Oct;66(10Suppl2):S116-24.
  107. Haber DN Roads leading to breast cancer. Engl J Med. 2000 Nov 23;343(21):1566-8.
  108. Sarrel PM, Njike VY, Vinante V, Katz DL. The mortality toll of estrogen avoidance: An analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health. 2013 Jul 18.
  109. Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med. 2009 Nov;122(11):1016-1022.
  110. Yenugonda VM, Kong Y, Deb TB, Yang Y, Riggins RB, Brown ML. Trans-resveratrol boronic acid exhibits enhanced anti-proliferative activity on estrogen-dependent MCF-7 breast cancer cells. Cancer Biol Ther. 2012 Aug;13(10):925-34.
  111. Khan MA, Chen HC, Wan XX, et al. Regulatory effects of resveratrol on antioxidant enzymes: a mechanism of growth inhibition and apoptosis induction in cancer cells. Mol Cells. 2013 Mar;35(3):219-25.
  112. Smolarek AK, So JY, Burgess B, et al. Dietary administration of δ- and γ-tocopherol inhibits tumorigenesis in the animal model of estrogen receptor-positive, but not HER-2 breast cancer. Cancer Prev Res (Phila). 2012 Nov;5(11):1310-20.
  113. Smolarek AK, Suh N. Chemopreventive activity of vitamin E in breast cancer: a focus on γ- and δ-tocopherol. Nutrients. 2011 Nov;3(11):962-86.
  114. Gopalan A, Yu W, Jiang Q, Jang Y, Sanders BG, Kline K. Involvement of de novo ceramide synthesis in gamma-tocopherol and gamma-tocotrienol-induced apoptosis in human breast cancer cells. Mol Nutr Food Res. 2012 Dec;56(12):1803-11.
  115. Alvarez-García V, González A, Martínez-Campa C, Alonso-González C, Cos S. Melatonin modulates aromatase activity and expression in endothelial cells. Oncol Rep. 2013 May;29(5):2058-64.
  116. Cos S, González A, Güezmes A, et al. Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer. 2006 Jan 15;118(2):274-8.
  117. Cos S, González A, Martínez-Campa C, et al. Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Targets. 2008 Dec;8(8):691-702.
  118. Montales MT, Rahal OM, Nakatani H, Matsuda T, Simmen RC. Repression of mammary adipogenesis by genistein limits mammosphere formation of human MCF-7 cells. J Endocrinol. 2013 Jun 1;218(1):135-49.
  119. Dave B, Eason RR, Till SR, et al. The soy isoflavone genistein promotes apoptosis in mammary epithelial cells by inducing the tumor suppressor PTEN. Carcinogenesis. 2005 Oct;26(10):1793-803.